TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36216250

Group type: EXPERIMENTAL
Intervention: TiPEEK
Number of subjects: 82

Group type: COMPARATOR
Intervention: PEEK
Number of subjects: 82
Study: 33180175

Group type: EXPERIMENTAL
Intervention: Blonanserin (12.8 ± 5.6 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Olanzapine (10.8 ± 6.0 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Blonanserin (D3 receptor)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Olanzapine (D2 receptor)
Number of subjects: 13
Study: 33450668

Group type: EXPERIMENTAL
Intervention: Product A (Neocate)
Number of subjects: 0
Study: 35725457

Group type: EXPERIMENTAL
Intervention: Novel carbon-fibre adjustable reusable accessory (CARA) for supine positioning
Number of subjects: 220

Group type: COMPARATOR
Intervention: Current standard of care for supine positioning
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Novel device
Number of subjects: 220
Study: 35783867

Group type: EXPERIMENTAL
Intervention: Xinnaoning Capsule (XNNC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 32764878

Group type: EXPERIMENTAL
Intervention: Ondansetron administered 5 min before intrathecal injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ondansetron administered 15 min before intrathecal injection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo administered 5 min or 15 min before intrathecal injection
Number of subjects: 75
Study: 35219167

Group type: EXPERIMENTAL
Intervention: Low-residue diet (arm A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Free diet (arm B)
Number of subjects: 96
Study: 32219502

Group type: EXPERIMENTAL
Intervention: Scheduled combination therapy with carboplatin/paclitaxel plus oregovomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 35763763

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: CKD stages 2-5
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: eGFR values lower than 50 ml/min/1.73 m2
Number of subjects: 1064
Study: 35445718

Group type: EXPERIMENTAL
Intervention: Continuous treatment with Lucitanib
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with Lucitanib
Number of subjects: 20
Study: 33443695

Group type: EXPERIMENTAL
Intervention: Project ACTIVE intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 140
Study: 34511515

Group type: EXPERIMENTAL
Intervention: Combined intervention (CI) including non-nutritive sucking (NNS), oral motor stimulation, and oral support
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined intervention (CI)
Number of subjects: 44
Study: 35811140

Group type: EXPERIMENTAL
Intervention: Continuous nerve block analgesia via electronic pump
Number of subjects: 294

Group type: COMPARATOR
Intervention: Single injection analgesia
Number of subjects: 294
Study: 32168298

Group type: EXPERIMENTAL
Intervention: IV tirofiban infusion
Number of subjects: 52
Study: 35624492

Group type: EXPERIMENTAL
Intervention: Flipped classroom approach for simulation-based delirium management training
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flipped classroom approach
Number of subjects: 9
Study: 33848675

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (not specified dosage or duration)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 305
Study: 33316456

Group type: EXPERIMENTAL
Intervention: PARTICS + Usual Care
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1200
Study: 32053634

Group type: EXPERIMENTAL
Intervention: Flowchart-assisted standard resuscitation
Number of subjects: 84

Group type: COMPARATOR
Intervention: CC-only resuscitation
Number of subjects: 84
Study: 36308135

Group type: EXPERIMENTAL
Intervention: Viscoelastic-assisted nucleus removal (Group 1 - OVD)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Basal salt solution plus technique (Group 2 - BSS)
Number of subjects: 204
Study: 34719411

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride combined with midazolam
Number of subjects: 118

Group type: COMPARATOR
Intervention: Propofol combined with midazolam (Control)
Number of subjects: 118
Study: 32571684

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 48
Study: 35713701

Group type: EXPERIMENTAL
Intervention: Conservative access cavity (CAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Traditional access cavity (TAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Invasive access cavity (IAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Without access cavity (Control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Load-to-fracture test (all groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3D-FEA (all groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CBCT scans (CAC and TAC)
Number of subjects: 40
Study: 34001759

Group type: EXPERIMENTAL
Intervention: Evening training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Morning training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 33204084

Group type: EXPERIMENTAL
Intervention: ICS continuation
Number of subjects: 970

Group type: COMPARATOR
Intervention: ICS withdrawal
Number of subjects: 970

Group type: COMPARATOR
Intervention: ICS withdrawal in patients with a history of ≥2 exacerbations and blood eosinophil count ≥100 cells/μL
Number of subjects: 970

Group type: COMPARATOR
Intervention: ICS withdrawal in patients with a history of ≥2 exacerbations and blood eosinophil count ≥400 cells/μL
Number of subjects: 970
Study: 36058137

Group type: EXPERIMENTAL
Intervention: Active motion task
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resting state conditions
Number of subjects: 40
Study: 33947367

Group type: EXPERIMENTAL
Intervention: Medi‐Taping
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard treatment (patient education and physiotherapy)
Number of subjects: 110
Study: 34483279

Group type: EXPERIMENTAL
Intervention: MI-Walk intervention (8-week home-based brisk walking with motivational supports)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Physical activity (PA) education alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous PA (≥225 minutes per week)
Number of subjects: 57
Study: 33942724

Group type: EXPERIMENTAL
Intervention: 1% progesterone gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32227554

Group type: EXPERIMENTAL
Intervention: GSK2798745 (TRPV4 antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 35774072

Group type: EXPERIMENTAL
Intervention: TRACE (online communication skills training)
Number of subjects: 10375

Group type: EXPERIMENTAL
Intervention: INTRO (online communication skills training)
Number of subjects: 10375
Study: 33059997

Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) brachytherapy, prescription dose 144 Gy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cesium-131 (131Cs) brachytherapy, prescription dose 115 Gy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) brachytherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cesium-131 (131Cs) brachytherapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) and Cesium-131 (131Cs) brachytherapy
Number of subjects: 140
Study: 34077627

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Continuous UST
Number of subjects: 941
Study: 32376640

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 3 months
Number of subjects: 160
Study: 35437467

Group type: EXPERIMENTAL
Intervention: SNP rs17580 in TB patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: SNP rs17580 in dominant, recessive, and codominant models
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Comparison of genotypes in smoking TB patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Comparison of genotypes in alcoholic TB patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Time to cure among 3 genotypes in TB patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Type mutation of rs17580 in SERPINA1 gene
Number of subjects: 420
Study: 34543285

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 80
Study: 32585017

Group type: EXPERIMENTAL
Intervention: Sildenafil, 25 mg, 3 times a day
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 34261807

Group type: EXPERIMENTAL
Intervention: Genicular nerve blockade (15 mL 0.25% bupivacaine and 2 mg dexamethasone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo (SHAM group)
Number of subjects: 40
Study: 33834250

Group type: EXPERIMENTAL
Intervention: Interviewer knowledge treatment (trained interviewers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 34017029

Group type: EXPERIMENTAL
Intervention: Pulse D therapy (60,000 IUs of vitamin D daily for 8 or 10 days depending on BMI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard treatment alone (NVD group)
Number of subjects: 130
Study: 33208170

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) boost after urgent 3D conformal radiotherapy (3DCRT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 7
Study: 35379238

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg up to three times daily
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 33071273

Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistance exercise plus leucine supplement (RL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study: 35786576

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30
Study: 34133981

Group type: EXPERIMENTAL
Intervention: Test product (amoxicillin 500mg) under fasted conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Test product (amoxicillin 500mg) under fed conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference product (amoxicillin 500mg) under fasted conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference product (amoxicillin 500mg) under fed conditions
Number of subjects: 16
Study: 32306991

Group type: EXPERIMENTAL
Intervention: Ginger tablets (126 tablets for six weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tablets (126 tablets for six weeks)
Number of subjects: 70
Study: 35767914

Group type: COMPARATOR
Intervention: Medium-level protein intake group
Number of subjects: 2191

Group type: EXPERIMENTAL
Intervention: Low-level protein intake group
Number of subjects: 2191

Group type: EXPERIMENTAL
Intervention: High-level protein intake group
Number of subjects: 2191
Study: 34215193

Group type: EXPERIMENTAL
Intervention: Systematic geriatric assessment added to standard care in the ED
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 432
Study: 35130946

Group type: EXPERIMENTAL
Intervention: whole cell pertussis (wP) vaccine
Number of subjects: 3000

Group type: COMPARATOR
Intervention: acellular pertussis (aP) vaccine
Number of subjects: 3000
Study: 32290521

Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acids (LEAAs) 4 g thrice daily for four days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acids (LEAAs)
Number of subjects: 20
Study: 32533536

Group type: EXPERIMENTAL
Intervention: ASP4345 (3–150 mg multiple oral doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP4345 (3–900 mg single oral doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASP4345 (300 mg single oral dose)
Number of subjects: 0
Study: 35135010

Group type: EXPERIMENTAL
Intervention: Health warning label (HWL) on menu
Number of subjects: 96

Group type: COMPARATOR
Intervention: No health warning label on menu (Control)
Number of subjects: 96
Study: 33199274

Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg subcutaneous every 4 weeks (Q4W)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg intravenous every 8 weeks (Q8W)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Fasinumab 6 mg
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg intravenous
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 32949954

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Classical music listening (ML)
Number of subjects: 27
Study: 34799300

Group type: EXPERIMENTAL
Intervention: Trident™ P2 respirator
Number of subjects: 500

Group type: COMPARATOR
Intervention: 3M™ Aura™ 9320A + N95 respirator
Number of subjects: 500
Study: 34351590

Group type: EXPERIMENTAL
Intervention: Oliceridine (0.1, 0.35, or 0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled data of Oliceridine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled data of Morphine
Number of subjects: 0
Study: 36127535

Group type: EXPERIMENTAL
Intervention: Population healthcare (n = 1341)
Number of subjects: 2713

Group type: COMPARATOR
Intervention: Usual care (n = 1372)
Number of subjects: 2713
Study: 33319930

Group type: EXPERIMENTAL
Intervention: Immediate delivery (n=26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Temporizing management (n=30)
Number of subjects: 56
Study: 32724156

Group type: EXPERIMENTAL
Intervention: Azelaic acid (AA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pyruvic acid (PA)
Number of subjects: 120
Study: 33356640

Group type: EXPERIMENTAL
Intervention: Multimodal exercises integrated with cognitive-behavioural therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: General physiotherapy
Number of subjects: 150
Study: 34834083

Group type: EXPERIMENTAL
Intervention: Ojeok-San (OJS)
Number of subjects: 20
Study: 32686643

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34407037

Group type: EXPERIMENTAL
Intervention: Heparinized solution 100 U/mL (10 mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Heparinized solution 10 U/mL (20 mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Heparinized solution 10 U/mL (30 mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Urokinase solution
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Heparin at 10 U/mL
Number of subjects: 81
Study: 35659521

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 35435424

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol + Sevoflurane
Number of subjects: 70
Study: 32531798

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 2 weeks (Q2W)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 995
Study: 32473887

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCBs)
Number of subjects: 0
Study: 35129852

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 175

Group type: COMPARATOR
Intervention: Shallow puncture
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nonacupoint deep puncture
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nonacupoint shallow puncture
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nonpenetration acupuncture
Number of subjects: 175
Study: 34538851

Group type: EXPERIMENTAL
Intervention: Device B: superpower sound processor with a higher MFO
Number of subjects: 19

Group type: COMPARATOR
Intervention: Device A: standard sound processor with a lower MFO
Number of subjects: 19
Study: 35468321

Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled 10 mg and 15 mg)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 243
Study: 33493170

Group type: EXPERIMENTAL
Intervention: Exposure to violence in the last year
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Male doctors experiencing abuse
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Female doctors experiencing abuse
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Doctors in governmental medical centers
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Type of abuse reported by doctors in governmental centers
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Mean score of worry regarding workplace violence
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Belief in protection by law
Number of subjects: 969
Study: 36045192

Group type: EXPERIMENTAL
Intervention: Checklist-guided medication review and communication stimulus
Number of subjects: 609

Group type: COMPARATOR
Intervention: Usual discharge routines
Number of subjects: 609
Study: 35311298

Group type: EXPERIMENTAL
Intervention: Tootling intervention
Number of subjects: 0
Study: 33020105

Group type: EXPERIMENTAL
Intervention: Nasal high flow during neonatal intubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (no nasal high flow)
Number of subjects: 0
Study: 34189841

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 1842
Study: 32113757

Group type: EXPERIMENTAL
Intervention: High-fat CMR
Number of subjects: 32
Study: 35698974

Group type: EXPERIMENTAL
Intervention: Unblinded n-of-1 trial
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Blinded n-of-1 trial
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: N-of-1 trials (both unblinded and blinded)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Comparison between unblinded and blinded arms
Number of subjects: 93
Study: 33429736

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic hepatectomy (LH)
Number of subjects: 0
Study: 36034568

Group type: EXPERIMENTAL
Intervention: AI-assisted group (Smart-doctor)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 740
Study: 32886401

Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 at 200 pmol/kg/min (Clamp D)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 at 2000 pmol/kg/min (Clamp E)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Clamp F)
Number of subjects: 8
Study: 35225634

Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of psychotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Weekly sessions of psychotherapy
Number of subjects: 200
Study: 32157684

Group type: EXPERIMENTAL
Intervention: PREPARE plus an easy‐to‐read advance directive (AD)
Number of subjects: 393

Group type: COMPARATOR
Intervention: AD alone
Number of subjects: 393
Study: 34493496

Group type: EXPERIMENTAL
Intervention: Enhanced therapy (usual care plus measuring skin temperatures at 6-8 plantar sites per foot each day)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Enhanced therapy (with hotspot monitoring and activity reduction)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual care (podiatric treatment, education, and therapeutic footwear)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Enhanced therapy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study: 33129314

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (booklet, video, home visit, telephone call)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 234
Study: 34164675

Group type: EXPERIMENTAL
Intervention: Oligo/Amen + Cal (n=40)
Number of subjects: 76
Study: 32443977

Group type: EXPERIMENTAL
Intervention: Suchana program interventions delivered to 40 randomly selected unions annually over 4 years, including normal government nutrition services.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group consisting of the last 40 unions that will not receive the Suchana program interventions.
Number of subjects: 157
Study: 35065867

Group type: EXPERIMENTAL
Intervention: Parasternal long (PSL) view
Number of subjects: 6247

Group type: COMPARATOR
Intervention: Subxiphoid (SX) view
Number of subjects: 6247
Study: 32919816

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly)
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly) in participants with 25(OH)D < 50 nmol/L
Number of subjects: 5108

Group type: COMPARATOR
Intervention: Placebo in participants with 25(OH)D < 50 nmol/L
Number of subjects: 5108
Study: 32730181

Group type: EXPERIMENTAL
Intervention: Bortezomib, Melphalan, and Dexamethasone (BMDex)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Melphalan and Dexamethasone (MDex)
Number of subjects: 109
Study: 34180035

Group type: EXPERIMENTAL
Intervention: Fostemsavir (HIV-1 attachment inhibitor)
Number of subjects: 0
Study: 33514049

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of tweets related to panic buying of toilet paper
Number of subjects: 500
Study: 35446209

Group type: EXPERIMENTAL
Intervention: Telehealth home monitoring (part of the REACH randomized clinical trial)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 148